Jefferies Financial Group Research Analysts Raise Earnings Estimates for Progyny, Inc. (NASDAQ:PGNY)


Progyny, Inc. (NASDAQ:PGNYGet Rating) – Investment analysts at Jefferies Financial Group increased their FY2023 earnings estimates for Progyny in a report issued on Monday, May 9th. Jefferies Financial Group analyst G. Santangelo now expects that the company will earn $0.77 per share for the year, up from their prior estimate of $0.75.

A number of other equities research analysts have also recently commented on PGNY. TheStreet cut shares of Progyny from a “c-” rating to a “d+” rating in a report on Friday, January 28th. Zacks Investment Research upgraded shares of Progyny from a “hold” rating to a “buy” rating and set a $38.00 price target on the stock in a report on Thursday. Two research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Buy” and an average target price of $65.86.

Shares of NASDAQ PGNY opened at $33.06 on Thursday. The company has a 50 day simple moving average of $43.91 and a two-hundred day simple moving average of $46.82. Progyny has a fifty-two week low of $32.06 and a fifty-two week high of $68.32. The company has a market capitalization of $3.03 billion, a price-to-earnings ratio of 59.04, a P/E/G ratio of 12.42 and a beta of 2.01.

Progyny (NASDAQ:PGNYGet Rating) last announced its earnings results on Monday, February 28th. The company reported $0.15 earnings per share for the quarter, beating analysts’ consensus estimates of $0.04 by $0.11. Progyny had a net margin of 10.09{21df340e03e388cc75c411746d1a214f72c176b221768b7ada42b4d751988996} and a return on equity of 24.50{21df340e03e388cc75c411746d1a214f72c176b221768b7ada42b4d751988996}. The business had revenue of $127.55 million during the quarter, compared to the consensus estimate of $134.87 million. During the same quarter last year, the firm earned $0.07 earnings per share. The business’s revenue for the quarter was up 27.2{21df340e03e388cc75c411746d1a214f72c176b221768b7ada42b4d751988996} on a year-over-year basis.

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. First Horizon Advisors Inc. raised its position in Progyny by 1,469.4{21df340e03e388cc75c411746d1a214f72c176b221768b7ada42b4d751988996} in the fourth quarter. First Horizon Advisors Inc. now owns 769 shares of the company’s stock worth $38,000 after acquiring an additional 720 shares during the period. Fifth Third Bancorp raised its position in Progyny by 1,532.4{21df340e03e388cc75c411746d1a214f72c176b221768b7ada42b4d751988996} in the fourth quarter. Fifth Third Bancorp now owns 1,208 shares of the company’s stock worth $61,000 after acquiring an additional 1,134 shares during the period. Steward Partners Investment Advisory LLC raised its position in Progyny by 44.8{21df340e03e388cc75c411746d1a214f72c176b221768b7ada42b4d751988996} in the fourth quarter. Steward Partners Investment Advisory LLC now owns 1,209 shares of the company’s stock worth $61,000 after acquiring an additional 374 shares during the period. Exane Derivatives bought a new position in Progyny in the first quarter worth approximately $69,000. Finally, Captrust Financial Advisors raised its position in Progyny by 19.1{21df340e03e388cc75c411746d1a214f72c176b221768b7ada42b4d751988996} in the third quarter. Captrust Financial Advisors now owns 1,566 shares of the company’s stock worth $88,000 after acquiring an additional 251 shares during the period. Institutional investors and hedge funds own 82.51{21df340e03e388cc75c411746d1a214f72c176b221768b7ada42b4d751988996} of the company’s stock.

In related news, CEO Peter Anevski sold 600 shares of the firm’s stock in a transaction that occurred on Friday, February 11th. The shares were sold at an average price of $42.00, for a total value of $25,200.00. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, Chairman David J. Schlanger sold 1,000 shares of the firm’s stock in a transaction that occurred on Friday, February 11th. The stock was sold at an average price of $42.00, for a total transaction of $42,000.00. The disclosure for this sale can be found here. Insiders sold 535,366 shares of company stock worth $22,823,122 in the last 90 days. 14.00{21df340e03e388cc75c411746d1a214f72c176b221768b7ada42b4d751988996} of the stock is currently owned by corporate insiders.

About Progyny (Get Rating)

Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions for employers in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.

See Also

Earnings History and Estimates for Progyny (NASDAQ:PGNY)



Receive News & Ratings for Progyny Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Progyny and related companies with MarketBeat.com’s FREE daily email newsletter.

Minnie Arwood

Next Post

Latest Earnings, Stocks and Business News for May 11, 2022

Thu May 12 , 2022
The assembly line at Rivian’s plant in Ordinary, Sick., last month.Credit score…Kamil Krzaczynski/Reuters Rivian, the electric powered-motor vehicle maker that went public very last calendar year with massive ambitions to acquire on Tesla and some others, claimed Wednesday that offer-chain complications had hobbled it in the first quarter, but it […]
Latest Earnings, Stocks and Business News for May 11, 2022

You May Like